Own the gold standard ✨ in financial data & analytics

Subscribe for $2
Overview
Profile

CellaVision Company

CEVI.ST
SE0000683484
A0NEVD

Price

268.77
Today +/-
-0.94
Today %
-3.92 %
P

CellaVision stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the CellaVision stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the CellaVision stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the CellaVision stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze CellaVision's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

CellaVision Stock Price History

DateCellaVision Price
10/25/2024268.77 undefined
10/24/2024279.50 undefined
10/23/2024275.50 undefined
10/22/2024276.00 undefined
10/21/2024279.00 undefined
10/18/2024282.00 undefined
10/17/2024276.50 undefined
10/16/2024282.00 undefined
10/15/2024290.50 undefined
10/14/2024293.00 undefined
10/11/2024288.50 undefined
10/10/2024292.50 undefined
10/9/2024291.00 undefined
10/8/2024284.00 undefined
10/7/2024284.00 undefined
10/4/2024296.50 undefined
10/3/2024290.50 undefined
10/2/2024288.50 undefined
10/1/2024294.50 undefined
9/30/2024293.00 undefined
9/27/2024286.00 undefined
9/26/2024282.50 undefined

CellaVision Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into CellaVision, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by CellaVision from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects CellaVision’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of CellaVision. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into CellaVision’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing CellaVision’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on CellaVision’s growth potential.

CellaVision Revenue, EBIT and net profit per share

DateCellaVision RevenueCellaVision EBITCellaVision Net Income
2029e1.42 B undefined0 undefined0 undefined
2028e1.31 B undefined0 undefined0 undefined
2027e1.2 B undefined0 undefined0 undefined
2026e1.02 B undefined313.14 M undefined250.22 M undefined
2025e896.84 M undefined267.24 M undefined212.51 M undefined
2024e781.32 M undefined208.85 M undefined163.12 M undefined
2023677.29 M undefined167.05 M undefined130.31 M undefined
2022639.34 M undefined161.63 M undefined118.34 M undefined
2021565.55 M undefined162.73 M undefined125.34 M undefined
2020471.44 M undefined113.87 M undefined89.48 M undefined
2019461.77 M undefined126.58 M undefined99.17 M undefined
2018364.81 M undefined111.61 M undefined88.69 M undefined
2017309.31 M undefined90.89 M undefined69.72 M undefined
2016265.04 M undefined74.17 M undefined59.8 M undefined
2015239.39 M undefined65.47 M undefined52.82 M undefined
2014216.9 M undefined42.8 M undefined31.5 M undefined
2013179.9 M undefined25.9 M undefined18.9 M undefined
2012169.5 M undefined20.7 M undefined6.5 M undefined
2011155.4 M undefined17.8 M undefined14.6 M undefined
2010131.6 M undefined13.9 M undefined38.3 M undefined
2009109 M undefined14.8 M undefined27.7 M undefined
2008100.4 M undefined13.4 M undefined25.1 M undefined
200774.6 M undefined3.1 M undefined2.6 M undefined
200654.8 M undefined-8.6 M undefined-8.8 M undefined
200539 M undefined-16.5 M undefined-16.7 M undefined
200429.8 M undefined-26.6 M undefined-24.9 M undefined

CellaVision Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (B)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)DIV. ()DIV. GROWTH (%)SHARES (M)DOCUMENTS
200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024e2025e2026e2027e2028e2029e
0.010.010.020.030.040.050.070.10.110.130.160.170.180.220.240.270.310.360.460.470.570.640.680.780.91.021.21.311.42
-62.5015.3893.3334.4838.4637.0435.149.0020.1818.329.035.9220.6710.6510.8816.6017.8026.652.1719.9613.105.9515.3614.7213.2818.628.648.72
12.5030.7726.6734.4848.7259.2660.8163.0069.7266.4165.1665.0962.5767.1372.8070.9472.1774.1872.8966.4569.3868.5468.39------
14410193245637687101110112145174188223270336313392438463000000
-53-49-35-26-16-8313141317202542657490111126113162161167208267313000
-662.50-376.92-233.33-89.66-41.03-14.814.0513.0012.849.9210.9711.8313.9719.4427.2027.9229.1330.4927.3323.9928.6725.2024.6726.6329.8030.84---
-53-49-39-24-16-822527381461831525969889989125118130163212250000
--7.55-20.41-38.46-33.33-50.00-125.001,150.008.0040.74-63.16-57.14200.0072.2267.7413.4616.9527.5412.50-10.1040.45-5.6010.1725.3830.0617.92---
-----------------------------
-----------------------------
10.413.113.51920.623.923.923.923.923.923.923.923.923.923.8523.8523.8523.8523.8523.8523.8523.8523.85000000
-----------------------------
Details

Keystats

ⓘ

Revenue and Growth

The CellaVision Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the CellaVision is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
20012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023
                                             
49.739.25.119.217.616.816.319.62235.856.846.257.951.9106.7132.45154.55169.06102.31102.26130.29108.05121.65
5.53.74.56.49.111.411.632.625.535.226.740.643.360.535.533.2443.1675.8188.9271.0389.7497.6397.8
1.710.72.91.92.32.55.44.65.65.77.54.67.16.479.27.218.4814.1835.1824.4722.1912.05
9.38.178.813.57.448.49.17.514.516.416.825.124.6236.2828.7534.4554.8183.66115.09142.57126.04
1.51.310.80.80.81.10.61.31.22.32.93.24.53.995.265.776.765.035.945.146.78.06
67.753.318.338.142.938.735.566.662.585.3106113.6125.8149.1177.28216.43239.43294.57265.25298.07364.72377.14365.59
3.843.82.41.31.41.32.82.31.622.73.23.22.653.274.816.8254.4947.4380.33110.04125.5
00000000.10.10.10.10.10.10.21.22.032.623.5822.321.6522.015.344.4
0000000000000000000025.7624.260
13.811.38.44.60.91.37.414.92322.321.324.226.527.229.434.7253.7367.82184.55188.91244.08275.09309.44
7.85.10000000000000000115.12111.97114.09124.14123.78
22.30001.3001225.653.249.33833.122.59.900000000
47.720.412.273.52.78.729.85177.272.76562.953.143.1540.0261.1678.21376.46369.96486.25538.86563.12
115.473.730.545.146.441.444.296.4113.5162.5178.7178.6188.7202.2220.43256.45300.6372.78641.71668.03850.97916.01928.71
                                             
1.92233.63.63.63.63.63.63.63.63.63.63.583.583.583.583.583.583.583.583.58
0057.147.84223.31410.810.810.810.810.810.810.810.810.810.810.810.810.810.810.810.8
80.746.6-51.1-32.7-19-9.22.531.660.499111.7108.2117.6136.9169.14191.8224.05276.96339.99429.34537.07608.35685.09
000000000000.50.90002.42-0.96-5.99-14.11-8.1718.916.92
000000000001.8-0.30000000000
82.648.6818.126.617.720.14674.8113.4126.1124.9132.6151.3183.52206.18240.85290.38348.37429.62543.28641.63716.39
5.93.4243.17.86.117.213.811.116.516.510.612.37.3416.4521.4926.7521.7220.8744.8647.8632.53
2.52.932.63.13.43.33.96.41115.216.418.226.327.3327.5222.1335.0843.9930.236.8937.8345.52
4.43.72.12.43.447.28.54.76.15.26.57.212.32.255.057.510.059.397.2111.945.275.06
10.40.91.56.98.87.27.520.813.719.915.114200000000000
0000000000.90.60.200000050.7745.8740.8142.1336.04
23.210.98.615.918.422.424.150.438.64952.653.65650.936.9149.0251.1371.89125.86104.15134.5133.09119.15
9.513.813.41000000000000000122.9386.995.8560.3628.66
0000000000000001.256.228.0638.5443.3847.9552.9359.56
0.10.40.411.21.300000000002.42.466.013.983.643.744.95
9.614.213.8111.21.30000000001.258.6210.52167.47134.26147.43117.0393.17
32.825.122.426.919.623.724.150.438.64952.653.65650.936.9150.2759.7582.41293.34238.41281.93250.12212.32
115.473.730.44546.241.444.296.4113.4162.4178.7178.5188.6202.2220.43256.45300.6372.78641.71668.03825.21891.75928.71
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of CellaVision provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand CellaVision's financial health and stability.

Assets

CellaVision's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that CellaVision must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of CellaVision after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into CellaVision's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES (M)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
20012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023
-53-49-39-26-16-8213101018182443657590112129112158148164
566551103667812788620033400
00000000000000000000000
-50-2-4-782-172-88-12-7-1514-8-10-45-21-56-40-55-17
00311005320-1100000-2158449
11000000000000000012120
00000000000000000000000
-53-41-31-24-160612011321127398775877412571159137196
-12-3-300-1-7-11-11-4-5-11-11-13-9-14-29-22-18-33-52-69-86
-12-3-200-1-7-11-11-4-5-11-11-13-9-15-29-23-266-34-84-70-85
000000000000000000-247-1-3100
00000000000000000000000
8-403-8-1013-77-5-15-190000108-35-30-42-43
511603324100000000000000000
5434038150013-77-5-10-3-31-23-35-35-3572-35-48-90-97
-522010000000000000000000
00000000000-9-9-11-23-35-35-35-350-17-47-53
-11-10-3414-100321321-1011-554252214-66028-2213
-65.6-44.63-34.57-24.7-17-0.86-1.02-9.999.476.7326.110.3815.4826.0478.861.3258.851.17107.3137.53107.2168.05109.96
00000000000000000000000

CellaVision stock margins

The CellaVision margin analysis displays the gross margin, EBIT margin, as well as the profit margin of CellaVision. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for CellaVision.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the CellaVision's sales revenue. A higher gross margin percentage indicates that the CellaVision retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the CellaVision's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the CellaVision's total revenue generated. When comparing the revenue margin year over year, investors can gauge the CellaVision's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the CellaVision. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the CellaVision's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

CellaVision Margin History

CellaVision Gross marginCellaVision Profit marginCellaVision EBIT marginCellaVision Profit margin
2029e68.37 %0 %0 %
2028e68.37 %0 %0 %
2027e68.37 %0 %0 %
2026e68.37 %30.85 %24.65 %
2025e68.37 %29.8 %23.7 %
2024e68.37 %26.73 %20.88 %
202368.37 %24.66 %19.24 %
202268.56 %25.28 %18.51 %
202169.37 %28.77 %22.16 %
202066.4 %24.15 %18.98 %
201972.92 %27.41 %21.48 %
201874.25 %30.59 %24.31 %
201772.17 %29.39 %22.54 %
201671.29 %27.98 %22.56 %
201572.78 %27.35 %22.07 %
201466.9 %19.73 %14.52 %
201362.59 %14.4 %10.51 %
201264.96 %12.21 %3.83 %
201165.25 %11.45 %9.4 %
201066.57 %10.56 %29.1 %
200970.18 %13.58 %25.41 %
200863.25 %13.35 %25 %
200760.72 %4.16 %3.49 %
200658.39 %-15.69 %-16.06 %
200550.26 %-42.31 %-42.82 %
200435.23 %-89.26 %-83.56 %

CellaVision Stock Sales Revenue, EBIT, Earnings per Share

The CellaVision earnings per share therefore indicates how much revenue CellaVision has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue CellaVision earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates CellaVision's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of CellaVision’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating CellaVision's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

CellaVision Revenue, EBIT and net profit per share

DateCellaVision Sales per ShareCellaVision EBIT per shareCellaVision Earnings per Share
2029e59.62 undefined0 undefined0 undefined
2028e54.84 undefined0 undefined0 undefined
2027e50.48 undefined0 undefined0 undefined
2026e42.55 undefined0 undefined10.49 undefined
2025e37.6 undefined0 undefined8.91 undefined
2024e32.76 undefined0 undefined6.84 undefined
202328.4 undefined7 undefined5.46 undefined
202226.8 undefined6.78 undefined4.96 undefined
202123.71 undefined6.82 undefined5.25 undefined
202019.77 undefined4.77 undefined3.75 undefined
201919.36 undefined5.31 undefined4.16 undefined
201815.29 undefined4.68 undefined3.72 undefined
201712.97 undefined3.81 undefined2.92 undefined
201611.11 undefined3.11 undefined2.51 undefined
201510.04 undefined2.74 undefined2.21 undefined
20149.08 undefined1.79 undefined1.32 undefined
20137.53 undefined1.08 undefined0.79 undefined
20127.09 undefined0.87 undefined0.27 undefined
20116.5 undefined0.74 undefined0.61 undefined
20105.51 undefined0.58 undefined1.6 undefined
20094.56 undefined0.62 undefined1.16 undefined
20084.2 undefined0.56 undefined1.05 undefined
20073.12 undefined0.13 undefined0.11 undefined
20062.29 undefined-0.36 undefined-0.37 undefined
20051.89 undefined-0.8 undefined-0.81 undefined
20041.57 undefined-1.4 undefined-1.31 undefined

CellaVision business model

CellaVision AB is an internationally leading company in the development of systems for automated cell imaging and analysis, founded in 1994 in Lund, Sweden. CellaVision is one of the most popular companies on Eulerpool.com.

CellaVision SWOT Analysis

Strengths

1. Technological Expertise: CellaVision AB has built a strong reputation in the market for its advanced technologies in digital microscopy and image analysis.

2. High Quality Products: The company offers high-quality automated hematology analyzers and related software solutions, ensuring accuracy and reliability for its customers.

3. Strong Market Presence: CellaVision AB has established a dominant position in the global hematology market, providing innovative solutions to healthcare institutions worldwide.

Weaknesses

1. Limited Product Portfolio: The company's product portfolio predominantly focuses on hematology analysis, which leaves it vulnerable to market fluctuations and lack of diversification.

2. Dependence on Key Customers: CellaVision AB relies on a few major customers for a significant portion of its revenue, exposing it to potential risks if these relationships deteriorate.

3. Intense Competition: The industry is highly competitive, with several global players vying for market share. CellaVision AB needs to continuously innovate and adapt to maintain its competitive edge.

Opportunities

1. Growing Healthcare Market: The increasing demand for efficient and advanced hematology analyzers presents an opportunity for CellaVision AB to expand its customer base.

2. Emerging Markets: The company can explore untapped markets in developing countries where the adoption of automated hematology analyzers is on the rise.

3. Technological Advancements: Continual advancements in imaging and analysis technologies open doors for CellaVision AB to develop innovative solutions and capture new market segments.

Threats

1. Regulatory Challenges: Changing regulations and compliance requirements in the healthcare industry may pose challenges for CellaVision AB, leading to increased costs and restricted market access.

2. Economic Volatility: Uncertain economic conditions could impact healthcare budgets, potentially reducing the demand for CellaVision AB's products.

3. Technological Obsolescence: Rapid technological advancements could render current products obsolete, necessitating constant investment in research and development to stay ahead.

CellaVision Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

CellaVision historical P/E ratio, EBIT multiple, and P/S ratio

CellaVision shares outstanding

The number of shares was CellaVision in 2023 — This indicates how many shares 23.852 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue CellaVision earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates CellaVision's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of CellaVision’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating CellaVision's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

CellaVision dividend history and estimates

In 2023, CellaVision paid a dividend amounting to 2.25 SEK. Dividend means that CellaVision distributes a portion of its profits to its owners.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Dividend
Dividend (Estimate)
Details

Dividend

ⓘ

Dividend Overview

The dividend per year chart for CellaVision provides a comprehensive view of the annual dividends distributed to shareholders. Analyze the trend to understand the consistency and growth in dividend payouts over the years.

Interpretation and Use

A consistent or increasing trend in dividends can indicate the company's profitability and financial health. Investors can use this data to identify CellaVision’s potential for long-term investment and income generation through dividends.

Investment Strategy

Incorporate the dividend data in evaluating CellaVision's overall performance. A thorough analysis, considering other financial aspects, will help in making informed investment decisions for optimal capital growth and income generation.

CellaVision Dividend History

DateCellaVision Dividend
2029e2.54 undefined
2028e2.54 undefined
2027e2.54 undefined
2026e2.54 undefined
2025e2.53 undefined
2024e2.55 undefined
20232.25 undefined
20222 undefined
20210.75 undefined
20191.5 undefined
20181.5 undefined
20171.5 undefined
20161.5 undefined
20151 undefined
20140.5 undefined
20130.4 undefined
20120.4 undefined

CellaVision dividend payout ratio

In 2023, CellaVision had a payout ratio of 28.27%. The payout ratio indicates the percentage of the company's profits that CellaVision distributes as dividends.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Payout ratio
Details

Payout ratio

ⓘ

What is Yearly Payout Ratio?

The yearly payout ratio for CellaVision represents the proportion of earnings paid out as dividends to shareholders. It is an indicator of the company's financial health and stability, illustrating how much profit is being returned to investors versus being reinvested back into the company.

How to Interpret the Data

A lower payout ratio for CellaVision could mean that the company is reinvesting more into its growth, whereas a higher ratio indicates more earnings are being distributed as dividends. Investors seeking regular income might prefer companies with a higher payout ratio, while those looking for growth may opt for companies with a lower ratio.

Using the Data for Investments

Evaluate CellaVision's payout ratio in conjunction with other financial metrics and performance indicators. A sustainable payout ratio, coupled with strong financial health, can indicate a reliable dividend payout. However, a very high ratio might suggest the company is not sufficiently reinvesting in its future growth.

CellaVision Payout Ratio History

DateCellaVision Payout ratio
2029e29.78 %
2028e30.35 %
2027e29.67 %
2026e29.32 %
2025e32.07 %
2024e27.62 %
202328.27 %
202240.31 %
202114.27 %
202030.21 %
201936.06 %
201840.34 %
201751.31 %
201659.83 %
201545.16 %
201437.88 %
201350.63 %
2012148.15 %
201130.21 %
201030.21 %
200930.21 %
200830.21 %
200730.21 %
200630.21 %
200530.21 %
200430.21 %
Unfortunately, there are currently no price targets and forecasts available for CellaVision.

CellaVision latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
6/30/20241.73 1.62  (-6.57 %)2024 Q2
3/31/20241.48 1.26  (-14.81 %)2024 Q1
12/31/20231.53 2.11  (37.6 %)2023 Q4
9/30/20231.34 1.09  (-18.63 %)2023 Q3
6/30/20231.2 1.46  (21.99 %)2023 Q2
3/31/20231.09 0.81  (-26.01 %)2023 Q1
12/31/20221.57 1.35  (-14.24 %)2022 Q4
9/30/20221.29 0.44  (-65.76 %)2022 Q3
6/30/20221.52 1.56  (2.65 %)2022 Q2
3/31/20221.39 1.61  (15.64 %)2022 Q1
1
2
3
4
...
5

Eulerpool ESG Scorecard© for the CellaVision stock

Eulerpool World ESG Rating (EESG©)

51/ 100

🌱 Environment

48

👫 Social

57

🏛️ Governance

49

Environment

Scope 1 - Direct Emissions
—
Scope 2 - Indirect emissions from purchased energy
—
Scope 3 - Indirect emissions within the value chain
—
Total CO₂ emissions
539
CO₂ reduction strategy
✅
Coal energy
❌
Nuclear power
❌
Animal experiments
❌
Fur & Leather
—
Pesticides
—
Palm Oil
—
Tobacco
❌
Genetically modified organisms
❌
Climate concept
—
Sustainable forestry
—
Recycling regulations
❌
Environmentally friendly packaging
❌
Hazardous substances
❌
Fuel consumption and efficiency
❌
Water consumption and efficiency
❌

Social

Percentage of female employees46
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content❌
Alcohol❌
Weapons—
Firearms
❌
Gambling❌
Military contracts❌
Human rights concept✅
Privacy concept—
Occupational health and safety✅
Catholic✅

Governance (Corporate Governance)

Environmental reporting✅
Stakeholder Engagement❌
Call Back Policies❌
Antitrust law❌

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

CellaVision shareholders

%
Name
Stocks
Change
Date
19.92746 % Oticon Fonden4,752,99902/28/2023
10.02453 % Grenlunden CEVI AB2,391,00002/28/2023
8.37353 % SEB Investment Management AB1,997,21216,0392/28/2023
8.08502 % Fåhraeus (Christer)1,928,39902/28/2023
5.00130 % Swedbank Robur Fonder AB1,192,885120,0007/24/2023
4.52199 % Invesco Advisers, Inc.1,078,56201/31/2024
3.03526 % Fjärde AP-Fonden723,95558,5862/28/2023
2.62120 % Candriam Belgium S.A.625,195-106,0072/28/2023
2.33018 % AMF Tjänstepension AB555,78402/28/2023
2.22906 % Handelsbanken Kapitalförvaltning AB531,665-9,3103/31/2024
1
2
3
4
5
...
10

CellaVision Executives and Management Board

Mr. Simon Oestergaard52
CellaVision President, Chief Executive Officer
Compensation 6.62 M
Mr. Mikael Worning61
CellaVision Independent Chairman of the Board
Compensation 680,000
Ms. Asa Hedin61
CellaVision Independent Director
Compensation 412,500
Mr. Christer Fahraeus58
CellaVision Director, Founder (since 1998)
Compensation 265,000
Mr. Stefan Wolf59
CellaVision Independent Director
Compensation 242,500
1
2
3

Most common questions regarding CellaVision

What values and corporate philosophy does CellaVision represent?

CellaVision AB represents a set of core values and a corporate philosophy that underpin its operations. The company is committed to excellence, innovation, and customer satisfaction. Through its cutting-edge technologies and solutions, CellaVision aims to revolutionize hematology analysis and improve patient care. With a focus on quality, CellaVision strives to deliver accurate and reliable results, empowering healthcare professionals worldwide. Moreover, the company fosters a culture of collaboration, teamwork, and transparency to drive advancements in the field of medical diagnostics. By embodying these values, CellaVision AB remains dedicated to its mission of transforming healthcare through intelligent automation and efficient laboratory workflows.

In which countries and regions is CellaVision primarily present?

CellaVision AB is primarily present in various countries and regions around the world. With its global reach, the company has established its presence in countries such as Sweden, the United States, and various European and Asian markets. CellaVision AB's extensive global footprint allows it to cater to a diverse customer base and expand its market share internationally.

What significant milestones has the company CellaVision achieved?

CellaVision AB, a renowned company in the stock market, has achieved several significant milestones throughout its journey. These include the development and launch of cutting-edge hematology analyzers, such as the CellaVision DM96 and CellaVision DC-1. The company has also expanded its global presence, establishing strategic partnerships with various leading healthcare organizations worldwide. Furthermore, CellaVision AB has consistently demonstrated its commitment to innovation by continuously enhancing its product portfolio and introducing advanced digital solutions in the field of automated blood and body fluid analysis. With its relentless pursuit of excellence and industry recognition, CellaVision AB stands as a remarkable player in the stock market.

What is the history and background of the company CellaVision?

CellaVision AB is a leading global provider of advanced digital solutions for medical microscopy in the field of hematology. Founded in 1994, CellaVision has a rich history in developing and supplying innovative products that revolutionize the analysis of blood and other body fluids. The company's breakthrough technologies enable automated digital microscopy, accelerating and improving the diagnostic workflow in clinical laboratories. CellaVision's solutions offer healthcare professionals increased efficiency, accuracy, and patient safety, ultimately contributing to better healthcare outcomes. With a strong commitment to research and development, CellaVision continues to pioneer advancements in digital hematology, establishing itself as a trusted name in the industry.

Who are the main competitors of CellaVision in the market?

The main competitors of CellaVision AB in the market include Sysmex Corporation, Roche Diagnostics, and Beckman Coulter.

In which industries is CellaVision primarily active?

CellaVision AB is primarily active in the medical technology industry.

What is the business model of CellaVision?

The business model of CellaVision AB focuses on developing and selling digital solutions for medical laboratories worldwide. CellaVision offers an innovative range of products, including automated digital systems for advanced blood cell analysis and software solutions for efficient lab management. The company's solutions aim to improve lab productivity, quality, and patient care by streamlining workflow processes and enhancing the accuracy of blood cell analysis. CellaVision AB stands as a leading provider in the field of hematology diagnostics, enabling healthcare professionals to make better-informed decisions for optimizing patient outcomes.

What is the P/E ratio of CellaVision 2024?

The CellaVision P/E ratio is 39.3.

What is the P/S ratio of CellaVision 2024?

The CellaVision P/S ratio is 8.2.

What is the Quality Investing of CellaVision?

The Quality Investing for CellaVision is 10/10.

What is the revenue of CellaVision 2024?

The expected CellaVision revenue is 781.32 M SEK.

How high is the profit of CellaVision 2024?

The expected CellaVision profit is 163.12 M SEK.

What is the business model of CellaVision

CellaVision AB is a leading provider of digital solutions for automated blood cell analysis. The company, based in Lund, Sweden, was founded in 1994 and now employs over 350 people.

What is the CellaVision dividend?

CellaVision pays a dividend of 2 SEK distributed over payouts per year.

How often does CellaVision pay dividends?

The dividend cannot currently be calculated for CellaVision or the company does not pay out a dividend.

What is the CellaVision ISIN?

The ISIN of CellaVision is SE0000683484.

What is the CellaVision WKN?

The WKN of CellaVision is A0NEVD.

What is the CellaVision ticker?

The ticker of CellaVision is CEVI.ST.

How much dividend does CellaVision pay?

Over the past 12 months, CellaVision paid a dividend of 2.25 SEK . This corresponds to a dividend yield of about 0.84 %. For the coming 12 months, CellaVision is expected to pay a dividend of 2.53 SEK.

What is the dividend yield of CellaVision?

The current dividend yield of CellaVision is 0.84 %.

When does CellaVision pay dividends?

CellaVision pays a quarterly dividend. This is distributed in the months of May, June, June, June.

How secure is the dividend of CellaVision?

CellaVision paid dividends every year for the past 0 years.

What is the dividend of CellaVision?

For the upcoming 12 months, dividends amounting to 2.53 SEK are expected. This corresponds to a dividend yield of 0.91 %.

In which sector is CellaVision located?

CellaVision is assigned to the 'Health' sector.

Wann musste ich die Aktien von CellaVision kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of CellaVision from 5/13/2024 amounting to 2.25 SEK, you needed to have the stock in your portfolio before the ex-date on 5/6/2024.

When did CellaVision pay the last dividend?

The last dividend was paid out on 5/13/2024.

What was the dividend of CellaVision in the year 2023?

In the year 2023, CellaVision distributed 2 SEK as dividends.

In which currency does CellaVision pay out the dividend?

The dividends of CellaVision are distributed in SEK.

All fundamentals about CellaVision

Our stock analysis for CellaVision Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of CellaVision Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.